Characteristics of patients who are initiated on long-acting buprenorphine (Buvidal®) in France: A retrospective cross-sectional study
Year: 2024
Type: article
Study design: Observational Study
Abstract: AIM: The long-acting buprenorphine Buvidal® is a recent type of opioid agonist treatment (OAT) used for opioid use disorder (OUD). It was initially suggested to preferentially use Buvidal® for specific OUD populations, including people in prison, or patients in recovery and on sublingual buprenorphine. We conducted a national study to examine whether the profile of patients treated with Buvidal® in France matched these initial recommendations. METHODS: A retrospective cross-sectional study was conducted in 13 national addiction centers (outside prison), using the individual medical records of patients initiated on Buvidal®. Baseline characteristics were collected and described, including sociodemographic features, comorbid medical conditions, concurrent substance use and prescription drug misuse, and OAT features before Buvidal® initiation, respectively. RESULTS: In total 101 patients (72.3% males, mean age 43.9±11.3years) were identified, which corresponded to one sixth of all patients treated with Buvidal® in France at the time of the study. Of them, 36 (36.4%) of them were professionally active, 35 (35.4%) were durably inactive, and the rest in an intermediary situation. Furthermore, 90 (90.0%) patients had at least one medical comorbidity (all types), and 83 (83.0%) at least one psychiatric comorbidity. Most frequent non-psychiatric comorbidities were chronic pain (n=20, 20.0%) and chronic viral infection (n=16, 17.8%). Current use of psychoactive substances included cocaine and crack (n=43, 42.6%), heroin (n=19, 18.8%), but also misuse of prescription drugs (n=20, 20%), mainly opioid analgesics. Moreover, 99 (98.0%) patients had an OAT before Buvidal® initiation, including 7 (8.1%) patients on methadone. CONCLUSION: The profile of patients initiated on Buvidal® in France was extremely similar to that of patients treated for OUD in France, either in terms of social or clinical features. While initial recommendations essentially underlined the interest of Buvidal® for some niche populations, the on-the-ground practice reveals a more widespread use, including for unrecovered patients, or patients treated with methadone.
Source: Therapies
Institutions: Assistance Publique – Hôpitaux de Paris, Inserm, Université de Bourgogne, CHU Dijon Bourgogne, Université Bourgogne Franche-Comté, Cognition, Action, and Sensorimotor Plasticity, Institut Pascal, Centre Hospitalier Universitaire de Clermont-Ferrand, Université de Clermont I, Hôpital Paul-Brousse, Université Paris Cité, Hôpital Fernand-Widal, Optimisation Thérapeutique en Neuropsychopharmacologie, Hospices Civils de Lyon, Centre Hospitalier Le Vinatier, Sorbonne Université, Pitié-Salpêtrière Hospital, Lyon 1 Université, Centre National de la Recherche Scientifique, Centre de Recherche en Neurosciences de Lyon
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,120
OpenAlex ID: W4403154472